[go: up one dir, main page]

MEP8409A - Fused heterocyclic compound - Google Patents

Fused heterocyclic compound

Info

Publication number
MEP8409A
MEP8409A MEP-84/09A MEP8409A MEP8409A ME P8409 A MEP8409 A ME P8409A ME P8409 A MEP8409 A ME P8409A ME P8409 A MEP8409 A ME P8409A
Authority
ME
Montenegro
Prior art keywords
optionally
atom
optionally substituted
ring structure
heterocyclic compound
Prior art date
Application number
MEP-84/09A
Other languages
Bosnian (bs)
English (en)
Inventor
Tomoyasu Ishikawa
Hiroshi Banno
Masaki Seto
Takahiko Taniguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of MEP8409A publication Critical patent/MEP8409A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MEP-84/09A 2004-06-02 2005-06-01 Fused heterocyclic compound MEP8409A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004165050 2004-06-02
JP2005058231 2005-03-02
PCT/JP2005/010451 WO2005118588A1 (ja) 2004-06-02 2005-06-01 縮合複素環化合物

Publications (1)

Publication Number Publication Date
MEP8409A true MEP8409A (en) 2011-12-20

Family

ID=35462874

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-84/09A MEP8409A (en) 2004-06-02 2005-06-01 Fused heterocyclic compound

Country Status (18)

Country Link
US (4) US7507740B2 (xx)
EP (1) EP1752457B1 (xx)
JP (2) JP4134227B2 (xx)
KR (1) KR101194622B1 (xx)
AU (1) AU2005250285B2 (xx)
BR (1) BRPI0511768A (xx)
CA (1) CA2569016C (xx)
CR (1) CR8827A (xx)
GE (1) GEP20105024B (xx)
IL (1) IL179414A (xx)
MA (1) MA28973B1 (xx)
ME (1) MEP8409A (xx)
MX (1) MXPA06013996A (xx)
NO (1) NO20066015L (xx)
NZ (1) NZ551938A (xx)
RU (1) RU2389731C2 (xx)
TW (1) TWI392679B (xx)
WO (1) WO2005118588A1 (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
EP1915377A1 (en) * 2005-07-22 2008-04-30 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
US20080161320A1 (en) * 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
EP2359825A2 (en) * 2006-10-06 2011-08-24 Takeda Pharmaceutical Company Limited Combination drug
MX2009006315A (es) * 2006-12-12 2009-10-13 Takeda Pharmaceutical Compuesto heterociclico fusionado.
US7825127B2 (en) * 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
WO2008124083A2 (en) * 2007-04-05 2008-10-16 Amgen Inc. Aurora kinase modulators and method of use
WO2008145681A2 (en) 2007-05-31 2008-12-04 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
US20100183604A1 (en) * 2007-06-19 2010-07-22 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
UY31684A (es) 2008-03-03 2009-11-10 Takeda Pharmaceutical Farmaco combinado
US20090233937A1 (en) * 2008-03-12 2009-09-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CA2716856C (en) 2008-03-20 2013-02-19 Amgen Inc. Aurora kinase modulators and method of use
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
WO2010036917A1 (en) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prevention and treatment of cancer with ras gene mutation
AR073679A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la no expresion de lkb1 supresion o mutacion, composicion farmaceutica. usos
WO2010036910A1 (en) * 2008-09-26 2010-04-01 Yoshikazu Ohta Heart protection by administering an amp-activated protein kinase activator
WO2010070032A1 (en) 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
DK2384327T3 (da) 2009-01-30 2013-10-28 Takeda Pharmaceutical Forbindelse med kondenseret ring og anvendelse deraf.
WO2011024871A1 (ja) * 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
WO2011040212A1 (en) 2009-10-01 2011-04-07 Takeda Pharmaceutical Company Limited Therapeutic agent for brain tumor
SI2513093T1 (sl) 2009-12-17 2014-11-28 Boehringer Ingelheim International Gmbh Novi CCR2 receptorski antagonisti in njihove uporabe
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
CA2760174A1 (en) * 2011-12-01 2013-06-01 Pharmascience Inc. Protein kinase inhibitors and uses thereof
TWI606049B (zh) * 2011-04-21 2017-11-21 原真股份有限公司 新穎激酶抑制劑
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
SI3049417T1 (sl) 2013-07-31 2019-03-29 Merck Patent Gmbh Piridini, pirimidini in pirazini kot inhibitorji BTK in njihove uporabe
US10040780B2 (en) * 2014-03-03 2018-08-07 The Regents Of The University Of California Mcl-1 antagonists
BR112016023623A2 (pt) 2014-04-25 2017-08-15 Pfizer compostos heteroaromáticos e seu uso como ligantes de dopamina d1
US9944649B2 (en) 2014-05-01 2018-04-17 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
CU24401B1 (es) 2014-05-01 2019-05-03 Novartis Ag Compuestos derivados de metoxibencil-pirrolopirimidin-amina como agonistas del receptor tipo toll 7 (tlr7)
JP6917910B2 (ja) 2015-07-02 2021-08-11 セントレクシオン セラピューティクス コーポレイション （４−（（３ｒ，４ｒ）−３−メトキシテトラヒドロ−ピラン−４−イルアミノ）ピペリジン−１−イル）（５−メチル−６−（（（２ｒ，６ｓ）−６−（ｐ−トリル）テトラヒドロ−２ｈ−ピラン−２−イル）メチルアミノ）ピリミジン−４イル）メタノンクエン酸塩
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3591845B1 (en) * 2018-07-05 2023-08-09 Universite De Bretagne Sud Sorting device and method for elementary check node processing for message-passing decoding of non-binary codes
WO2020118183A1 (en) * 2018-12-06 2020-06-11 Kapoor Tarun M 2,4-diaminopyrimidine bicycles for treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS554116B2 (xx) * 1971-08-20 1980-01-29
ATE151423T1 (de) * 1993-06-21 1997-04-15 Merrell Pharma Inc Carbocyclische nucleoside mittel nützlich als selektive inhibitoren von proinflammatorischen cytokinen
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
PT831829E (pt) * 1995-06-07 2003-12-31 Pfizer Derivados de pirimidina heterociclicos de aneis fundidos
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
DK0836605T3 (da) * 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
DE69710712T3 (de) 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
AR007855A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
EP0938486B1 (en) * 1996-08-23 2008-01-16 Novartis AG Substituted pyrrolopyrimidines and processes for their preparation
CA2217373A1 (en) 1996-10-10 1998-04-10 Michael John Martin Benzo¬b|thiophene compounds, intermediates, formulations, and methods
BR9713552A (pt) * 1996-11-27 2000-01-25 Pfizer Derivados de pirimidina bicìclicos condensados
KR20010022583A (ko) 1997-08-05 2001-03-26 데이비드 존 우드 뉴로펩티드 Ｙ 수용체 길항제로서의 4-아미노피롤(3,2-ｄ)피리미딘
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
ATE266662T1 (de) * 1998-07-22 2004-05-15 Daiichi Suntory Pharma Co Ltd Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
EP1206559A2 (en) * 1999-08-26 2002-05-22 Plant Research International B.V. Conditional inhibition of vegetative propagation
HUP0304054A2 (hu) 2001-04-30 2004-04-28 Glaxo Group Limited A kortikotropin-realising faktor (CRF) antagonistáiként alkalmazható kondenzált pirimidinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
RU2003134646A (ru) 2001-04-30 2005-04-20 Глэксо Груп Лимитед (GB) Конденсированные пиримидины в качестве антагонистов кортикотропинвысокобождающего фактора (crf)
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
JP2003183283A (ja) * 2001-12-18 2003-07-03 Takeda Chem Ind Ltd 縮合インドール化合物、その製造法および用途
EP1348707B1 (en) * 2002-03-28 2010-08-25 Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
BRPI0410720A (pt) * 2003-05-27 2006-06-20 Pfizer Prod Inc quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
JP2006020985A (ja) 2004-07-05 2006-01-26 Kiyoshi Owada 微小孔を用いた入浴剤用炭酸ガス拡散装置
MX2007001216A (es) * 2004-07-30 2007-03-23 Methylgene Inc Inhibidores de la senalizacion del receptor del factor de crecimiento endotelial vascular y del receptor del factor de crecimiento del hepatocito.
DK1904504T3 (da) * 2005-05-20 2014-06-23 Methylgene Inc Inhibitorer af vegf-receptor- og hgf-receptorsignalering
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
EP2359825A2 (en) * 2006-10-06 2011-08-24 Takeda Pharmaceutical Company Limited Combination drug
US20100183604A1 (en) * 2007-06-19 2010-07-22 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
US20090233937A1 (en) * 2008-03-12 2009-09-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound

Also Published As

Publication number Publication date
JP2008247907A (ja) 2008-10-16
CA2569016A1 (en) 2005-12-15
RU2389731C2 (ru) 2010-05-20
CA2569016C (en) 2012-11-27
CR8827A (es) 2007-04-20
RU2006147267A (ru) 2008-07-20
TWI392679B (zh) 2013-04-11
US20090018335A1 (en) 2009-01-15
KR101194622B1 (ko) 2012-10-29
JP4937172B2 (ja) 2012-05-23
AU2005250285B2 (en) 2011-08-18
KR20070026695A (ko) 2007-03-08
BRPI0511768A (pt) 2008-01-08
WO2005118588A1 (ja) 2005-12-15
NO20066015L (no) 2007-02-13
IL179414A0 (en) 2007-05-15
US7507740B2 (en) 2009-03-24
NZ551938A (en) 2010-07-30
JPWO2005118588A1 (ja) 2008-04-03
MA28973B1 (fr) 2007-11-01
US20070244132A1 (en) 2007-10-18
JP4134227B2 (ja) 2008-08-20
IL179414A (en) 2013-11-28
US20090029973A1 (en) 2009-01-29
TW200611907A (en) 2006-04-16
AU2005250285A1 (en) 2005-12-15
EP1752457A4 (en) 2010-05-26
EP1752457B1 (en) 2014-03-19
US8178543B2 (en) 2012-05-15
EP1752457A1 (en) 2007-02-14
GEP20105024B (en) 2010-06-25
US20090203717A1 (en) 2009-08-13
MXPA06013996A (es) 2007-02-08

Similar Documents

Publication Publication Date Title
MEP8409A (en) Fused heterocyclic compound
EA200800873A1 (ru) Конденсированные гетероциклические соединения, полезные в качестве модуляторов киназы
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
MY153045A (en) Oxopyrazine derivative and herbicide
CY1111922T1 (el) 1-ετεροκυκλυλσουλφονυλ, 2-αμινομεθυλ, 5-(ετερο-)αρυλ υποκατεστημενα 1-η-πυρρολιου παραγωγα ως αναστολεις εκκρισης οξεος
CY1113099T1 (el) Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2
EA200971061A1 (ru) Пиримидоновые соединения гетероариламидов
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
ATE556058T1 (de) 1-(2h)-isochinolonderivat
BRPI0508966A (pt) composto, composição farmacêutica, e, uso de um composto
MY142018A (en) Thiophene derivatives as chk 1 inihibitors
BRPI0619894B8 (pt) composto de amina e composição farmacêutica
NO20084701L (no) Ny heterocyklisk forbindelse eller salt eller intermediat derav
ATE478044T1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
MX2010008362A (es) Derivados de heteroarilamida diazepinopirimidona sustituidos.
TW200602319A (en) Indole derivative and use thereof
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
MX2010008360A (es) Derivados de oxazepinopirimidona heteroarilamida sustituidos.
ATE503746T1 (de) Neue imidazolidinderivate
MY183326A (en) New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
MY141784A (en) Phenylpyridylpiperazine compounds
MX2007008308A (es) Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1-.